“Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants”
The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.
Drug - Pexidartinib
Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects